Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Senseonics Holdings, Inc. Common Stock (NASDAQ:SENS) have received an average rating of “Moderate Buy” from the seven research firms that are presently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $22.70.

SENS has been the topic of several recent research reports. TD Cowen reaffirmed a “buy” rating on shares of Senseonics Holdings, Inc. Common Stock in a research note on Thursday, January 8th. Stifel Nicolaus set a $9.00 target price on shares of Senseonics Holdings, Inc. Common Stock in a research note on Tuesday, March 3rd. Finally, Weiss Ratings started coverage on shares of Senseonics Holdings, Inc. Common Stock in a research note on Tuesday, February 17th. They set a “sell (d-)” rating on the stock.

Senseonics Holdings, Inc. Common Stock Price Performance

Senseonics Holdings, Inc. Common Stock stock opened at $6.68 on Thursday. Senseonics Holdings, Inc. Common Stock has a 1 year low of $5.25 and a 1 year high of $15.74. The company has a market capitalization of $279.16 million, a PE ratio of -3.95 and a beta of 1.04. The company has a current ratio of 4.83, a quick ratio of 4.55 and a debt-to-equity ratio of 0.58.

Insider Activity at Senseonics Holdings, Inc. Common Stock

In other news, CEO Timothy T. Goodnow purchased 17,225 shares of the stock in a transaction on Friday, March 13th. The stock was bought at an average price of $5.79 per share, for a total transaction of $99,732.75. Following the acquisition, the chief executive officer directly owned 651,243 shares of the company’s stock, valued at approximately $3,770,696.97. The trade was a 2.72% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Douglas A. Roeder purchased 17,500 shares of the stock in a transaction on Friday, March 13th. The shares were purchased at an average price of $5.73 per share, with a total value of $100,275.00. Following the acquisition, the director directly owned 119,731 shares in the company, valued at $686,058.63. This represents a 17.12% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 3.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in SENS. Smith Salley Wealth Management grew its holdings in Senseonics Holdings, Inc. Common Stock by 10.9% during the 3rd quarter. Smith Salley Wealth Management now owns 61,000 shares of the company’s stock worth $27,000 after acquiring an additional 6,000 shares in the last quarter. HBK Sorce Advisory LLC purchased a new position in shares of Senseonics Holdings, Inc. Common Stock in the 3rd quarter valued at $39,000. Ausdal Financial Partners Inc. grew its position in shares of Senseonics Holdings, Inc. Common Stock by 50.0% in the 3rd quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock valued at $46,000 after buying an additional 35,000 shares during the last quarter. Goldstone Financial Group LLC purchased a new position in shares of Senseonics Holdings, Inc. Common Stock in the 3rd quarter valued at $52,000. Finally, GSK plc purchased a new position in shares of Senseonics Holdings, Inc. Common Stock in the 4th quarter valued at $60,000. Institutional investors and hedge funds own 12.36% of the company’s stock.

About Senseonics Holdings, Inc. Common Stock

Senseonics Holdings, Inc develops and commercializes long-term implantable continuous glucose monitoring (CGM) systems for people with diabetes. The company’s primary product family is the Eversense system, which combines a small subcutaneously implanted sensor, a removable external transmitter, and companion smartphone applications to provide continuous glucose readings and alerts. Senseonics positions its technology as an alternative to wearable patch-style CGMs by offering multi-month sensor longevity and on-body vibration alerts delivered through the transmitter.

Senseonics supports clinical and commercial activities that include research and development, regulatory engagement, manufacturing and distribution, and training for healthcare providers who perform sensor insertion and removal.